Table 3 Biologics approved for IMIDs: FDA, EMEA and NICE.
| Biologic agent | Action | FDA licence | EMEA licence | NICE approval |
|---|---|---|---|---|
| Infliximab | Anti‐TNFα | RA | RA | RA |
| AS | AS | PsA | ||
| PsA | PsA | CD | ||
| CD | CD | AS (appraisal) | ||
| UC | UC | UC (submitted) | ||
| Paediatric CD | Psoriasis | Psoriasis | ||
| Paediatric CD (appraisal) | ||||
| Etanercept | Anti‐TNFα | RA | RA | RA |
| JIA | JIA | JIA | ||
| AS | AS | PsA | ||
| PsA | PsA | Psoriasis | ||
| Psoriasis | Psoriasis | AS (appraisal) | ||
| Adalimumab | Anti‐TNFα | RA | RA | RA (appraisal) |
| PsA | PsA | PsA | ||
| AS | AS | AS | ||
| Rituximab | Anti‐CD20 | RA | RA | RA (submitted) |
| Abatacept | CTLA4Ig | RA | RA (submitted) | RA (submitted) |
| Efalizumab | Anti‐CD11a | Psoriasis | Psoriasis | Psoriasis |
| Alefacept | LFA‐3/IgG Fc construct | Psoriasis | None | None |
| Anakinra | Anti‐IL1 | RA | RA | None |
AS, ankylosing spondylitis; CD, Crohn's disease; CTLA4, cytotoxic T lymphocyte antigen‐4; EMEA, European Medicines Agency; FDA, US Food and Drug Administration; IL, interleukin; JIA, juvenile idiopathic arthritis; NICE, UK National Institute for Health and Clinical Excellence; PsA, psoriatic arthritis; RA, rheumatoid arthritis; TNFα, tumour necrosis factor‐α; UC, ulcerative colitis.